Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma. (PubMed, Ann Hematol) - Sep 17, 2026 - "We report on a 58-year-old male with high-risk IgA kappa multiple myeloma who was heavily pretreated and received idecabtagene vicleucel as sixth-line therapy, achieving a deep response lasting for approximately one year. Following disease progression, the patient received bridging therapy with mezigdomide,carfilzomib, and dexamethasone, followed by a second BCMA-directed CAR T-cell infusion using ciltacabtagene autoleucel...Bridging therapy and the use of an alternative CAR T-cell construct may further improve outcomes. Prospective studies are needed to define optimal patient selection and treatment sequencing in this setting."
IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology
|
|
Anna Bold; Henrik Niklas; Johannes Gärtner; Knut Wendelin; Marietta Truger; Nicola Lang; Simon Völkl; Stefan Knop; Susanne Strifler
|